# Understanding the burden of ANCA-associated vasculitis

## TL;DR

This paper reviews the challenges of ANCA-associated vasculitis, focusing on its impact on patients and ways to improve their quality of life.

## Contribution

The paper provides a comprehensive review of disease burden and strategies to improve outcomes in ANCA-associated vasculitis.

## Key findings

- Immunosuppression therapies improve remission and survival in AAV patients.
- Mortality remains high due to treatment-related comorbidities and infections.
- Strategies to improve quality of life are discussed.

## Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of frequently relapsing systemic autoimmune disorders characterized by vasculitis-related organ damage and multiple comorbidities related to chronic inflammation. Advances in immunosuppression-based therapies for AAV have considerably improved remission rates, reduced the risk of relapse, and improved survival in patients with AAV. However, mortality remains high compared with the general population and the benefits of treatment are often offset by treatment-related comorbidities, organ damage and adverse effects, particularly infections. The aim of this review is to investigate the key contributors to disease burden in patients with AAV and to describe strategies for improving health-related quality of life.